Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Capital Employed (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Capital Employed for 11 consecutive years, with 0.57% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 51.0% to 0.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.57% through Dec 2025, up 51.0% year-over-year, with the annual reading at 0.67% for FY2025, 21.0% up from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.57% at ImmunityBio, up from 0.65% in the prior quarter.
  • The five-year high for Return on Capital Employed was 14.9% in Q2 2022, with the low at 7.05% in Q1 2022.
  • Average Return on Capital Employed over 5 years is 0.47%, with a median of 0.97% recorded in 2024.
  • The sharpest move saw Return on Capital Employed skyrocketed 1665bps in 2022, then plummeted -1364bps in 2023.
  • Over 5 years, Return on Capital Employed stood at 12.09% in 2021, then tumbled by -80bps to 2.45% in 2022, then plummeted by -136bps to 0.88% in 2023, then decreased by -22bps to 1.08% in 2024, then soared by 47bps to 0.57% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.57%, 0.65%, and 0.94% for Q4 2025, Q3 2025, and Q2 2025 respectively.